Followers | 22 |
Posts | 4027 |
Boards Moderated | 1 |
Alias Born | 08/18/2017 |
Wednesday, July 20, 2022 3:28:55 PM
With a Senate bill to federally legalize marijuana expected to be introduced imminently, a key subcommittee chaired by one of the measure’s prime sponsors has scheduled a hearing for next week on cannabis reform and the harms of criminalization.
The Senate Judiciary Subcommittee on Crime and Terrorism, chaired by Sen. Cory Booker (D-NJ), will meet on July 26 for a meeting titled “Decriminalizing Cannabis at the Federal Level: Necessary Steps to Address Past Harms.”
While details are limited, it’s reasonable to assume that senators on the panel will be discussing long-awaited legislation from Booker, Senate Majority Leader Chuck Schumer (D-NY) and Senate Finance Committee Chairman Ron Wyden (D-OR), which Senate sources recently told Marijuana Moment could be filed as early as this week.
That bill—the Cannabis Administration & Opportunity Act (CAOA)—was released in draft form a little over a year ago. Advocates and stakeholders have been eagerly awaiting its introduction, and the timeline for the filing has been repeatedly pushed back as the sponsors have worked across the aisle to solicit feedback and build buy-in, but Schumer has made a “promise” that it would drop before the August recess.
Now with a key subcommittee headed by a sponsor scheduling a meeting on the specific issue it addresses, it seems that CAOA’s introduction is likely less than a week away. Marijuana Moment reached out to Schumer’s and Booker’s offices for comment, but representatives were not immediately available.
—
Marijuana Moment is tracking more than 1,500 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.
https://www.marijuanamoment.net/senate-schedules-marijuana-hearing-in-committee-chaired-by-cory-booker-with-legalization-bill-set-to-drop-any-day/
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM